Any psychotropic (N=3587) | Antidepressants (N06A) (N=3660) | Anxiolytics (N05B) (N=3867) | Sedatives and hypnotics (N05C) (N=3808) | |||||||||
n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | |
Job control | ||||||||||||
High–high | 1477 (402) | 1.00 | Reference | 1499 (264) | 1.00 | Reference | 1573 (102) | 1.00 | Reference | 1559 (245) | 1.00 | Reference |
High–low | 506 (148) | 1.08 | 0.90 to 1.31 | 518 (95) | 1.04 | 0.82 to 1.32 | 542 (43) | 1.22 | 0.86 to 1.74 | 532 (94) | 1.13 | 0.89 to 1.43 |
Low–high | 417 (117) | 1.03 | 0.84 to 1.27 | 425 (80) | 1.06 | 0.83 to 1.36 | 457 (27) | 0.90 | 0.59 to 1.38 | 449 (91) | 1.33 | 1.04 to 1.69 |
Low–low | 1187 (341) | 1.08 | 0.94 to 1.25 | 1218 (244) | 1.18 | 0.99 to 1.41 | 1295 (113) | 1.37 | 1.05 to 1.79 | 1268 (205) | 1.03 | 0.86 to 1.24 |
Job demands | ||||||||||||
Low–low | 1188 (304) | 1.00 | Reference | 1208 (205) | 1.00 | Reference | 1267 (83) | 1.00 | Reference | 1254 (185) | 1.00 | Reference |
Low–high | 584 (165) | 1.09 | 0.90 to 1.32 | 598 (117) | 1.10 | 0.88 to 1.38 | 632 (45) | 1.05 | 0.73 to 1.52 | 619 (108) | 1.20 | 0.94 to 1.52 |
High–low | 601 (169) | 1.09 | 0.91 to 1.32 | 610 (106) | 1.01 | 0.80 to 1.27 | 649 (41) | 0.96 | 0.66 to 1.39 | 639 (110) | 1.16 | 0.92 to 1.47 |
High–high | 1214 (370) | 1.22 | 1.04 to 1.42 | 1244 (255) | 1.20 | 1.00 to 1.45 | 1319 (116) | 1.33 | 1.00 to 1.76 | 1296 (232) | 1.21 | 0.99 to 1.47 |
Physical work load | ||||||||||||
Low–low | 2351 (633) | 1.00 | Reference | 2390 (423) | 1.00 | Reference | 2508 (168) | 1.00 | Reference | 2480 (382) | 1.00 | Reference |
Low–high | 360 (112) | 1.17 | 0.96 to 1.43 | 371 (78) | 1.17 | 0.92 to 1.49 | 400 (26) | 1.09 | 0.74 to 1.62 | 384 (74) | 1.32 | 1.04 to 1.69 |
High–low | 359 (104) | 1.07 | 0.87 to 1.32 | 369 (63) | 0.93 | 0.71 to 1.21 | 396 (30) | 0.95 | 0.63 to 1.44 | 398 (80) | 1.25 | 0.96 to 1.60 |
High–high | 517 (159) | 1.17 | 0.98 to 1.39 | 530 (119) | 1.30 | 1.06 to 1.59 | 563 (61) | 1.66 | 1.24 to 2.23 | 546 (99) | 1.22 | 0.98 to 1.52 |
Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in 3 months preceding phase 2 were excluded.